In a statement made on X, FDA commissioner Marty Makary said: "FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products." "The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs." The commissioners remarks served as a clear warning to the telehealth company, which had emerged as a potential threat to the established revenue streams of pharma heavyweights such as Novo Nordisk and Eli Lilly
Alternatives when insurance does not cover tirzepatide Sometimes, despite your best efforts, insurance coverage is simply not available
For tirzepatide, subcutaneous administration is required
This is something she did with the guidance and support of her Ro-affiliated provider
At MTC, the focus is on personalized, medically responsible care rather than chasing unregulated online trends